Alzheimer’s blood testing momentum accelerated again as FDA cleared additional biomarker assays and diagnostic players moved to integrate them into routine lab workflows. Analysts pointed to a shift toward earlier placement in the diagnostic pathway when PET and CSF testing are less accessible. Roche and Eli Lilly’s clearance adds to a growing catalog of tau/amyloid blood tests, with companies increasingly emphasizing consistent clinical cutoffs across patient populations and instrument platforms. Lab operators’ commitments to nationwide rollout reflect a push to scale adoption. In parallel, market focus is shifting toward assay comparability and test positioning relative to confirmatory imaging, with the latest approvals shaping how clinicians order next-step evaluations.